WO2001085151A3 - Chimeric animal model and treatment of psoriasis - Google Patents
Chimeric animal model and treatment of psoriasis Download PDFInfo
- Publication number
- WO2001085151A3 WO2001085151A3 PCT/US2001/014988 US0114988W WO0185151A3 WO 2001085151 A3 WO2001085151 A3 WO 2001085151A3 US 0114988 W US0114988 W US 0114988W WO 0185151 A3 WO0185151 A3 WO 0185151A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psoriasis
- treatment
- animal model
- chimeric animal
- chimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001261324A AU2001261324A1 (en) | 2000-05-08 | 2001-05-08 | Psoriasis treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56657400A | 2000-05-08 | 2000-05-08 | |
US09/566,574 | 2000-05-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001085151A2 WO2001085151A2 (en) | 2001-11-15 |
WO2001085151A3 true WO2001085151A3 (en) | 2002-05-23 |
Family
ID=24263461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/014988 WO2001085151A2 (en) | 2000-05-08 | 2001-05-08 | Chimeric animal model and treatment of psoriasis |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001261324A1 (en) |
WO (1) | WO2001085151A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102623994B1 (en) | 2015-12-22 | 2024-01-11 | 장-노엘 또렐 | Composition comprising ambora extract and green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant itch and senile itch. |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004023832D1 (en) | 2003-05-16 | 2009-12-10 | Univ Laval | CNS CHLORIDE MODULATION AND USE THEREOF |
EP1653972A1 (en) * | 2003-07-23 | 2006-05-10 | Creabilis Therapeutics s.r.l. | Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation |
WO2005110490A1 (en) | 2004-05-14 | 2005-11-24 | Universite Laval | Phospholipase c gamma modulation and uses thereof for management of pain and nociception |
MX2008002524A (en) * | 2005-08-25 | 2008-03-14 | Creabilis Therapeutics Spa | Polymer conjugates of k-252a and derivatives thereof. |
ES2352929B1 (en) * | 2009-08-14 | 2012-01-26 | Centro De Investigaciones Energeticas. Medioamb Ientales Y Tecnologicas (Ciemat) | HUMANIZED PSORIASIS MODEL |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997038093A1 (en) * | 1996-04-05 | 1997-10-16 | Brigham & Women's Hospital, Inc. | Psoriasis model |
WO1997049406A1 (en) * | 1996-06-25 | 1997-12-31 | Cephalon, Inc. | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
WO1998044908A1 (en) * | 1997-04-07 | 1998-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Method of regulating epithelial growth |
WO2000001699A1 (en) * | 1998-07-02 | 2000-01-13 | Bayer Aktiengesellschaft | Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
WO2000016756A2 (en) * | 1998-09-24 | 2000-03-30 | Innovet Italia S.R.L. | Use of n-acylvanillinamide derivatives as agonists of peripheral cannabinoid cb1 receptors |
-
2001
- 2001-05-08 AU AU2001261324A patent/AU2001261324A1/en not_active Abandoned
- 2001-05-08 WO PCT/US2001/014988 patent/WO2001085151A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997038093A1 (en) * | 1996-04-05 | 1997-10-16 | Brigham & Women's Hospital, Inc. | Psoriasis model |
WO1997049406A1 (en) * | 1996-06-25 | 1997-12-31 | Cephalon, Inc. | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
WO1998044908A1 (en) * | 1997-04-07 | 1998-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Method of regulating epithelial growth |
WO2000001699A1 (en) * | 1998-07-02 | 2000-01-13 | Bayer Aktiengesellschaft | Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
WO2000016756A2 (en) * | 1998-09-24 | 2000-03-30 | Innovet Italia S.R.L. | Use of n-acylvanillinamide derivatives as agonists of peripheral cannabinoid cb1 receptors |
Non-Patent Citations (5)
Title |
---|
DAM T ET AL: "Pharmacological modulation of induction and treatment of psoriasis using human skin grafts transplanted onto SCID mice", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 108, no. 4, 1997, pages 572, XP001041554 * |
PINCELLI C ET AL: "Autocrine nerve growth factor in human keratinocytes", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 22, no. 2, February 1999 (1999-02-01), pages 71 - 79, XP001041596 * |
PINCELLI C: "Nerve growth factor and keratinocytes: a role in psoriasis.", EUR J DERMATOL, vol. 10, no. 2, March 2000 (2000-03-01), pages 85 - 90, XP002184137 * |
RAYCHAUDHURI S ET AL: "Role of neuroimmunologic inflammation in psoriasis in a SCID mouse-human skin animal model", FASEB J, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A1247, XP002184136 * |
YAMAMOTO T ET AL: "Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 17, no. 1, May 1998 (1998-05-01), pages 8 - 14, XP001041546 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102623994B1 (en) | 2015-12-22 | 2024-01-11 | 장-노엘 또렐 | Composition comprising ambora extract and green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant itch and senile itch. |
Also Published As
Publication number | Publication date |
---|---|
WO2001085151A2 (en) | 2001-11-15 |
AU2001261324A1 (en) | 2001-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002012190A3 (en) | Non-imidazole aryloxypiperidines as h3 receptor ligands | |
MX274785B (en) | Method for controlling particular insect pests by applying anthranilamide compounds. | |
AU2003267514A1 (en) | Method for making nitrile compounds from ethylenically unsaturated compounds | |
ZA200106683B (en) | Method for the preparation of citalopram. | |
HK1054378A1 (en) | Method for the preparation of citalopram. | |
MXPA03008630A (en) | Arylisoxazoline derivatives, method for production and use thereof as pesticides. | |
AU2003297197A1 (en) | Method for increasing the efficacy of agricultural chemicals | |
WO2004032908A3 (en) | Method of inhibiting angiogenesis | |
MXPA03001800A (en) | Process for the preparation of substituted phenylacetonitriles. | |
WO2001085151A3 (en) | Chimeric animal model and treatment of psoriasis | |
AU2003201163A1 (en) | Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol | |
WO2003002521A3 (en) | Method for production of azo compounds | |
ZA200303189B (en) | Method for producing a piece of timber including heartwood. | |
ZA200106158B (en) | Method for production of catalyst. | |
WO2002085915A3 (en) | Novel insecticidal azoles | |
ZA200106159B (en) | Method for production of catalyst. | |
ZA200104999B (en) | Method for the production of formaldehyde. | |
NO20041437L (en) | Method for improving soil by bio-explosion and providing microorganisms for this. | |
NO20050769L (en) | Method of introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | |
WO2003070696A3 (en) | Substituted aryl ketones | |
WO1999046263A3 (en) | Fungicidal benzoheterocyclyloxime | |
AU2003288255A8 (en) | Method for producing transgenic plants having an elevated vitamin E content by modifying the serine-acetyltransferase content | |
AU2001262470A1 (en) | Method for treating plant material, compositions comprising n-acylglucosamine derivatives, use of said compounds | |
IL150654A0 (en) | A METHOD FOR THE ISOLATION OF 6alpha,9alpha-DIFLUORO-11beta,17alpha-DIHYDROXY-16alpha-METHYLPREGNA-3-OXO-1,4-DIENE-17beta-CARBOXYLIC ACID | |
WO2001039787A3 (en) | Glyoxyl acid amides, method for producing them and their use for controlling harmful organisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |